Optimizing the "drug-like" properties of leads in drug discovery

書誌事項

Optimizing the "drug-like" properties of leads in drug discovery

Ronald T. Borchardt ... [et al.], editors

(Biotechnology : pharmaceutical aspects / Ronald T. Borchardt, C. Russell Middaugh, series editors, v. 4)

Springer, c2006

大学図書館所蔵 件 / 1

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery," which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process.

目次

Strategic Use of Preclinical Pharmacokinetic Studies and In Vitro Models in Optimizing ADME Properties of Lead Compounds.- Role of Mechanistic Transport Studies in Lead Optimization.- Metabolic Activation-Role in Toxicity and Idiosyncratic Reactions.- Case History - Use of ADME Studies for Optimization of Drug Candidates.- Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization.- Lipid-based Systems, Drug Exposure and Lead Optimization.- Biopharmaceutics Modeling and the Role of Dose and Formulation on Oral Exposure.- Application of Physicochemical Data to Support Lead Optimization by Discovery Teams.- Computational Models Supporting Lead Optimization in Drug Discovery.- Prodrug Strategies for Improving Drug-Like Properties.- The Application of Multivariate Data Analysis to Compound Property Optimization.- Case History: Toxicology Biomarker Development Using Toxicogenomics.- Predicting Idiosyncratic Drug Reactions.- Elementary Predictive Toxicology for Advanced Applications.- The Application of PK/PD Modeling and Simulations During Lead Optimization.- Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization.- Optimizing Biomarker Development for Clinical Studies at the Lead Optimization Stage of Drug Development.- The Relevance of Transporters in Determining Drug Disposition.

「Nielsen BookData」 より

関連文献: 1件中  1-1を表示

詳細情報

ページトップへ